Spotlight – scratching the surface of the urticaria pipeline
Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
Sanofi goes back to Scribe
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Pharma finds a way to gain weight
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
More details needed on Sanofi’s atopic dermatitis win
The anti-Ox40 ligand antibody amlitelimab could have its work cut out to best the company’s own Dupixent.
Hidradenitis suppurativa promise sends Moonlake soaring
Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.